PERSPECTIVE THERAPEUTICS, INC. (CATX)
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
📉 **NEGATIVE** • Medium confidence analysis (70%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (14%) **Content type:** Clinical